Study the Effects of IL7 (An Experimental Agent) on Patients with Prostate Cancer

What we are studying

The purpose of this study is to see if giving IL7 (an experimental biological product) after Provenge® improves the length and quality of your life.

Who is Eligible

  • Genders:
    • Men
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 90

Eligibility Criteria

  • Completion of standard treatment with Provenge

What is involved

  • Study participants randomized to receive IL7 will receive 1 injection a week for 4 weeks with 4 follow-up visits after injections are complete.



Contact Information

Study Coordinator
Patty Smith
[email protected]

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.